BeiGene, Ltd. (BGNE): Price and Financial Metrics
BeiGene, Ltd. (BGNE)
Today's Latest Price: $170.36 USD
2.51 (1.50%)
Updated Jan 17 12:00am
Add BGNE to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 213 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
BGNE Stock Summary
- BGNE's went public 3.96 years ago, making it older than just 13.14% of listed US stocks we're tracking.
- With a price/sales ratio of 23.29, BeiGene Ltd has a higher such ratio than 94.65% of stocks in our set.
- Revenue growth over the past 12 months for BeiGene Ltd comes in at 172.62%, a number that bests 96.34% of the US stocks we're tracking.
- Stocks that are quantitatively similar to BGNE, based on their financial statements, market capitalization, and price volatility, are XLRN, IDRA, AGIO, MCRB, and DRNA.
- Visit BGNE's SEC page to see the company's official filings. To visit the company's web site, go to www.beigene.com.
BGNE Daily Price Range
BGNE 52-Week Price Range
BGNE Stock Price Chart More Charts
BGNE Price/Volume Stats
| Current price | $170.36 | 52-week high | $210.35 |
| Prev. close | $167.85 | 52-week low | $113.01 |
| Day low | $167.53 | Volume | 350,700 |
| Day high | $171.91 | Avg. volume | 328,358 |
| 50-day MA | $181.84 | Dividend yield | N/A |
| 200-day MA | $143.44 | Market Cap | 10.40B |
BeiGene, Ltd. (BGNE) Company Bio
BeiGene, Ltd., a clinical-stage biopharmaceutical company, discovers and develops various oncology drugs in the People’s Republic of China. The company was founded in 2010 and is based in the Cayman Islands.
Top Stories View All
3 Vital Investing Strategies
Best & Worst Performing Stock Industries for January 17, 2020
Best & Worst Performing Small Cap Stocks for January 17, 2020
Best & Worst Performing Mid Cap Stocks for January 17, 2020
Best & Worst Performing Large Cap Stocks for January 17, 2020
View All Top Stories
Loading social stream, please wait...